Newsroom

NUEVA YORK--(BUSINESS WIRE)--Klarna (NYSE: KLAR), el banco digital global y proveedor de soluciones de pago flexibles, anunció hoy que ha presentado las solicitudes correspondientes ante el Departamento de Instituciones Financieras de Utah y la Corporación Federal de Seguro de Depósitos (FDIC) para crear Klarna Bank USA, un banco industrial regulado por el estado de Utah. Klarna opera como banco autorizado en Europa desde 2017 y presta servicio a sus clientes en Estados Unidos a través de una a...

马萨诸塞州列克星敦--(BUSINESS WIRE)--(美国商业资讯)-- 免疫肿瘤创新领域的领导者Agenus Inc. (Nasdaq: AGEN)今日公布了入组满员的C-800-01队列的三年里程碑式1b期数据。该队列评估了经Fc段增强的多功能抗CTLA-4抗体botensilimab (BOT)联合抗PD-1抗体balstilimab在治疗无活动性肝转移的难治性微卫星稳定型(MSS)转移性结直肠癌(mCRC)患者中的疗效。该数据于7月2日在德国慕尼黑举行的2026年欧洲肿瘤内科学会胃肠道肿瘤(ESMO GI)大会上公布。 BOT+BAL方案在既往接受过重度预治疗的患者群体中展现了具有临床意义的长期生存获益。这类患者群体历来从传统免疫检查点抑制剂中获益有限，且在标准治疗进展后很少有持久的治疗方案。随着随访时间的延长，患者的中位总生存期达到21.2个月，三年总生存率为33%，Kaplan-Meier曲线显示在两年后出现平台期。 在相关分析中，针对无活动性肝转移的难治性MSS mCRC，现有的后线标准治疗方案的历史中位总生存期约为10–14个月。这反映出在此类治疗环境中，过去极少有...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), een leider op het gebied van innovatie in de immuno-oncologie, heeft vandaag de Fase 1b-gegevens na drie jaar bekendgemaakt van het volledig ingeschreven C-800-01-cohort (fase 1b). Hierin werd de combinatie onderzocht van botensilimab (BOT) – een multifunctioneel anti-CTLA-4-antilichaam met verbeterde Fc-functie – en balstilimab (BAL) – een anti-PD-1-antilichaam – bij patiënten met refractair microsatelliet-stabiel (MSS) gemetastase...

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), líder em inovação em imuno-oncologia, anunciou hoje dados históricos de três anos da Fase 1b da coorte completa do estudo C-800-01. O estudo avaliou o botensilimab (BOT), um anticorpo multifuncional anti-CTLA-4 com expressão aumentada na região Fc, em combinação com o balstilimab (BAL), um anticorpo anti-PD-1, em pacientes com câncer colorretal metastático (CCRm) refratário, microssatélite estável (MSS), sem metástases hepát...

麻薩諸塞州萊辛頓--(BUSINESS WIRE)--(美國商業資訊)-- 免疫腫瘤創新領域的領導者Agenus Inc. (Nasdaq: AGEN)今日公布了招募滿員的C-800-01佇列的三年里程碑式第1b期資料。該佇列評估了經Fc段強化的多功能抗CTLA-4抗體botensilimab (BOT)聯合抗PD-1抗體balstilimab在治療無活動性肝轉移的難治性微衛星穩定型(MSS)轉移性大腸直腸癌(mCRC)病患中的療效。該資料於7月2日在德國慕尼黑舉行的2026年歐洲腫瘤內科學會胃腸道腫瘤(ESMO GI)大會上公布。 BOT+BAL方案在既往接受過重度預治療的病患群體中展現了具有臨床意義的長期生存獲益。這類病患群體歷來從傳統免疫檢查點抑制劑中獲益有限，且在標準治療進展後很少有持久的治療方案。隨著隨訪時間的延長，病患的中位整體存活期達到21.2個月，三年整體存活率為33%，Kaplan-Meier曲線顯示在兩年後趨於平穩。 在相關分析中，針對無活動性肝轉移的難治性MSS mCRC，現有的後線標準治療方案的歷史中位整體存活期約為10–14個月。這反映出在此類治療環境中，過去...

LOS ANGELES--(BUSINESS WIRE)--The TCW Group, a leading global investment firm, announced today that the TCW Strategic Income Fund, Inc. (NYSE: TSI) has declared a monthly distribution of $0.0283 per share payable on July 31, 2026, to shareholders of record on July 16, 2026.Distributions are based on the Fund’s accumulated net investment income and/or other sources for the applicable month. The Directors continue to monitor conditions and circumstances relating to the distribution of dividends an...

LOS ANGELES--(BUSINESS WIRE)--EQPT Investors Have Opportunity to Join EquipmentShare.com Inc. Fraud Investigation with the Schall Law Firm...

IRVINE, Calif.--(BUSINESS WIRE)--Rivian Automotive, Inc. (Nasdaq: RIVN) (“Rivian”) today announced that it has commenced an underwritten public offering of 75,000,000 shares of its common stock. In connection with the offering, Rivian expects to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions. All of the shares to be sold in the offering are to be sold by Rivia...

PHOENIX--(BUSINESS WIRE)--Western Alliance Bank (NYSE: WAL) today announced $33 million in construction financing for Marble Manor Phase I, a 138-unit, mixed-income housing redevelopment located less than two miles northwest of downtown Las Vegas, Nevada. The financing package includes a construction loan consisting of $31 million tax-exempt bonds and $2 million taxable bonds and $19.46 million in tax-exempt permanent bonds. R4 Capital Funding is Western Alliance’s originations partner and is t...

BURLINGAME, Calif.--(BUSINESS WIRE)--Upstart to Announce Second Quarter 2026 Results on August 4, 2026...